{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:02:28Z","timestamp":1792512148796,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of the study was to evaluate glucose metabolism, as measured by glycated hemoglobin (HbA1c) levels and the need for antidiabetic medical treatment, in patients with acromegaly resistant to first-generation somatostatin receptors ligands (SRLs) treated with pasireotide long-acting release (LAR) in real-world clinical practice. Biochemical control of acromegaly, as measured by growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels, was also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>Two-center retrospective cohort of consecutive patients with acromegaly treated with first-generation SRLs at maximum doses, who had not achieved biochemical disease control. After SRLs were discontinued, patients were given pasireotide LAR 40 mg i.m. every 28 days. The dose was increased to 60 mg i.m. in patients for whom adequate control was not achieved after 3 months. Patients were given dietary and lifestyle advice, and antihyperglycemic treatment was modified as needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Biochemical disease control parameters (GH and IGF-1 concentration), as well as HbA1c level at baseline and after 6\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 39 patients with acromegaly were enrolled. GH concentration decreased (\u0394\n                      <jats:sub>me<\/jats:sub>\n                      =-1.56\u00a0\u00b5g\/L, range -21.38\u20133.62, p &amp;lt;0.001) during 6 months of pasireotide LAR treatment. A worsening of metabolic status was observed, with an increase of median HbA1c (\u0394\n                      <jats:sub>me<\/jats:sub>\n                      =0.40%, range -0.20%\u20132.30%, p &amp;lt;0.001), and antihyperglycemic treatment intensification in 23 (59.0%) patients. The median decline in IGF-1 concentration was: -283.0\u00a0\u00b5g\/L, range -682.7\u2013171.6, p &amp;lt;0.001. IGF-1 reached the age- and gender-specific upper level of normal in 23 (59%) patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pasireotide LAR is an effective therapeutic option in patients with acromegaly refractory to first-generation SRLs. However, this therapy may result in pasireotide LAR-associated hyperglycemia, which requires early and aggressive antidiabetic medical therapy to prevent glucose homeostasis alterations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2021.633944","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T01:42:40Z","timestamp":1615340560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["The Effect of 6 Months\u2019 Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings"],"prefix":"10.3389","volume":"12","author":[{"given":"Przemys\u0142aw","family":"Witek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Bolanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Szamotulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Wojciechowska-Lu\u017aniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Jawiarczyk-Przyby\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Ka\u0142u\u017cny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra062453","article-title":"Acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0483-3","article-title":"Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations","volume":"17","author":"Colao","year":"2014","journal-title":"Pituitary"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01138-y","article-title":"Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study","volume":"43","author":"Colao","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S29125","article-title":"A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers","volume":"6","author":"Golor","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1690-5","article-title":"Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study","volume":"62","author":"Shimon","year":"2018","journal-title":"Endocrine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0332","article-title":"Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study","volume":"8","author":"Lasolle","year":"2019","journal-title":"Endocr Connect"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00358","article-title":"Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment","volume":"9","author":"Ferra\u00f9","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-1064","article-title":"French Acromegaly Registry Group. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"dgz096","DOI":"10.1007\/s11154-020-09588-z","article-title":"A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","unstructured":"Definition and diagnosis of diabetes and intermediate hyperglycaemia2006"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-020-00235-5","article-title":"Clinical presentation and management of acromegaly in elderly patients","volume":"20","author":"Ceccato","year":"2021","journal-title":"Hormones (Athens)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0253","article-title":"Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) Data base","volume":"24","author":"Petrossians","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/EJE-13-0032","article-title":"Effects of medical therapies for acromegaly on glucose metabolism","volume":"169","author":"Urbani","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1792-0","article-title":"Diabetes in patients with acromegaly treated with pegvisomant: observations from ACROSTUDY","volume":"63","author":"Brue","year":"2019","journal-title":"Endocrine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0615-y","article-title":"Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR","volume":"76","author":"Samson","year":"2016","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-014-0585-6","article-title":"Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study","volume":"18","author":"Sheppard","year":"2015","journal-title":"Pituitary"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE study)","volume":"103","author":"Muhammad","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1182-4","article-title":"ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study","volume":"55","author":"Fleseriu","year":"2017","journal-title":"Endocrine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-0895-8","article-title":"Effect of pasireotide on glucose- and growth hormone\u2013related biomarkers in patients with inadequately controlled acromegaly","volume":"53","author":"Schmid","year":"2016","journal-title":"Endocrine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.diabet.2012.10.005","article-title":"Management of hyperglycaemia in Cushing\u2019s disease: experts\u2019 proposals on the use of pasireotide","volume":"39","author":"Reznik","year":"2013","journal-title":"Diabetes Metab"},{"key":"B27","volume-title":"[summary of product characteristics]","year":"2014"},{"key":"B28","volume-title":"[package insert]","year":"2014"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.12.011","article-title":"Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study","volume":"103","author":"Breitschaft","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-1050","article-title":"Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry","volume":"164","author":"Fieffe","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.5603\/EP.2016.0066","article-title":"Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly","volume":"67","author":"Witek","year":"2016","journal-title":"Endokrynol Pol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2020.0050","article-title":"A. Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin\u00ae LAR\u00ae) in patients with acromegaly","volume":"71","author":"Bolanowski","year":"2020","journal-title":"Endokrynol Pol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.633944\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T01:42:46Z","timestamp":1615340566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.633944\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":33,"alternative-id":["10.3389\/fendo.2021.633944"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.633944","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739840515.793584645","asserted-by":"object"}]},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"article-number":"633944"}}